U.S. Markets close in 1 hr 34 mins
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    49,371.11
    +899.67 (+1.86%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MacroGenics Inc (NASDAQ: MGNX) and Zai Lab Limited (NASDAQ: ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.

  • The first collaboration program covers a lead research molecule that incorporates MacroGenics' DART platform and binds CD3 and an undisclosed target expressed in multiple solid tumors.

  • The second collaboration program will cover a target to be designated by MacroGenics.

  • Zai receives commercial rights in Greater China, Japan, and Korea and MacroGenics receives commercial rights in all other territories for both molecules.

  • Zai Lab receives an option upon reaching a predefined clinical milestone for the lead molecule to convert the regional arrangement into a global 50/50 profit share.

  • Zai Lab will also get exclusive, global licenses for two additional molecules.

  • Under the terms of the agreement, MacroGenics will receive an initial payment of $55 million, including an upfront payment of $25 million and an equity investment of $30 million at $31.30/share.

  • In addition, MacroGenics is eligible to receive up to $1.4 billion in potential milestone payments for the four programs.

  • If products from the collaboration are commercialized, MacroGenics would also receive royalties on annual net sales in Zai Lab's territories.

  • Price Action: MGNX shares are up by 7.37% at $22 during the premarket session on the last check Wednesday, while ZLAB closed at $166.1 on Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.